Gendrot M et al., 2020-10-16: French in vitro report that non-photoactivated methylene blue inhibits SARS-CoV-2 replication at sub-micromolar concentrations (EC50 0.30 micromolar, EC90 0.75 micromolar), lower than hydroxychloroquine and azithromycin, with blood Cmax/EC50 ratios of 10.1 after oral and 33.3 after intravenous dosing.
non-photoactivated methylene blue showed in vitro activity at very low micromolar range with an EC50 (median effective concentration) of 0.30 ± 0.03 μM and an EC90 (90% effective concentration) of 0.75 ± 0.21 μM at a multiplicity of infection (MOI) of 0.25 against SARS-CoV-2 (strain IHUMI-3).
Abstract
Gendrot M et al., 2020-10-16: French in vitro report that non-photoactivated methylene blue inhibits SARS-CoV-2 replication at sub-micromolar concentrations (EC50 0.30 micromolar, EC90 0.75 micromolar), lower than hydroxychloroquine and azithromycin, with blood Cmax/EC50 ratios of 10.1 after oral and 33.3 after intravenous dosing. Study type: in vitro (Vero E6 cells, SARS-CoV-2 strain IHUMI-3, MOI 0.25), RT-PCR readout; no light, no animals, no patients. Country: France (IHU Mediterranee Infection, Marseille). EC50 0.30 uM, EC90 0.75 uM; comparison compounds hydroxychloroquine (1.5/3.0 uM) and azithromycin (20.1/41.9 uM). Funder/COI not stated in the retrieved abstract record. Authors' own next step: 'In vivo evaluation in animal experimental models is now required'. Also filed as MTR-025 (claims C10, C3). Study type: lab.
